Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2021

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	98,635	$	34,224
Restricted cash, included in other assets		5,000		5,000
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	103,635	$	39,224

Schedule of the Company's net sales by medical indication

	Three Months Ended				Six Months Ended
(In thousands)	December 31,				December 31,
Medical Indication	2021		2020		2021		2020
Analgesic	$	3,919	$	3,572	$	9,233	$	6,692
Anti-Psychosis		2,095		13,317		5,810		26,345
Cardiovascular		9,753		16,336		23,853		36,050
Central Nervous System		22,340		24,614		45,125		47,139
Endocrinology		8,297		9,496		16,142		12,729
Gastrointestinal		14,023		18,575		29,263		35,675
Infectious Disease		6,520		23,044		19,035		44,976
Migraine		4,446		6,083		9,131		15,773
Respiratory/Allergy/Cough/Cold		1,868		2,267		4,982		3,693
Urinary		1,164		1,361		2,340		2,819
Other		9,111		8,410		18,287		16,044
Contract manufacturing revenue		2,972		6,845		4,832		12,464
Total net sales	$	86,508	$	133,920	$	188,033	$	260,399

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Product 1	5	%	15	%	8	%	15	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Customer A	26	%	26	%	28	%	26	%
Customer B	15	%	21	%	17	%	22	%
Customer C	14	%	12	%	14	%	11	%